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ABSTRACT
Objectives To establish the safety of an intranasal
diamorphine (IND) spray in children.
Design An open-label, single-dose pharmacovigilance
trial.
Setting Emergency departments in eight UK hospitals.
Participants Children aged 2–16 years with a fracture
or other trauma.
Outcome measures Adverse events (AE) speciﬁcally
related to nasal irritation, respiratory and central nervous
system depression.
Results 226 patients received 0.1 mg/kg IND. No
serious or severe AEs occurred. The incidence of
treatment-emergent AEs (TEAEs) was 26.5% (95% CI
20.9% to 32.8%), 93% being mild. 89% were related
to treatment, all being known effects of the drug or
route of administration except for three events in two
patients. 20.4% (95% CI 15.3% to 26.2%) patients
reported nasal irritation, all mild except one moderate
and one ‘unknown’ severity. No respiratory depression
was reported. Three AEs related to reduced Glasgow
Coma Score (GCS) occurred, all mild.
Conclusions There were no safety concerns raised
during the conduct of the study. In addition to expected
side effects, IND can cause mild nasal irritation in a
proportion of patients.
European Union Drug Regulating Authorities
Clinical Trial No 2009-014982-16.
INTRODUCTION
Urgent pain relief is required for children present-
ing with fractures and burns in the emergency
department (ED). Simple analgesics (eg, paraceta-
mol) are insufﬁcient to relieve severe pain; opiate
analgesia is usually needed. Oral opiates are
inappropriate due to delayed gastric emptying and
slow onset of action; rapid routes of administration
are necessary in the acute setting (ie, intravenous
and intranasal delivery).
Diamorphine is a semisynthetic derivative of
morphine that is licensed for moderate to severe
acute pain, usually administered by the intramuscu-
lar or intravenous routes in the UK and Ireland.
Diamorphine has properties that render it suitable
for administration via the nasal route.1 First, it has
good aqueous solubility, so a high dose can be
given in a small volume thus avoiding swallowing
excess solution which then enters the ﬁrst-pass
enterohepatic cycle of metabolism. Second, it is a
highly lipid soluble which provides a rapid onset of
action, as it crosses the blood-brain barrier more
readily than morphine. Diamorphine is a prodrug
of morphine which induces more rapid and more
intense central nervous system effects.1 2
Following initial efﬁcacy studies3 4 it has become
common practice in the UK to administer intranasal
diamorphine (IND) to children at a dose of 0.1 mg/
kg to relieve acute pain in the ED.5–7 The College of
Emergency Medicine and Advanced Paediatric Life
Support Guidelines recommend this practice,8 9 and
it is a treatment option in the British National
Formulary for Children.10 Currently, IND is used
off-label for children in approximately 55% of EDs
in the UK,6 7 usually between 3 years and 12 years
of age. Although there are randomised and open-
label studies to demonstrate the efﬁcacy of IND use
in children, IND has never been licensed as a medi-
cinal product. Consequently, systematic evaluation
of safety data of IND use in children are still
lacking.
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Key messages
What is known on this subject
▸ Intranasal diamorphine has an established role
in the treatment of children presenting to the
emergency department with acute moderate to
severe pain.
▸ Its use is recommended in guidelines produced
by the College of Emergency Medicine and the
Advanced Paediatric Life Support Group.
▸ At the time of the study diamorphine did not
have a licence for use as a nasal spray
What this study adds
▸ This paper reports data from a formal
pharmacovigilance trial of a new intranasal
diamorphine spray, Ayendi, used in children
presenting to the emergency department with
injuries requiring immediate pain relief.
▸ There were no serious or severe adverse events
amongst 226 children who received 0.1mg/kg
intranasal diamorphine. The overall incidence of
adverse events was 26.5%, 93% of which were
mild. 20.4% of patients reported nasal
irritation.
▸ Nasal diamorphine spray shows a good safety
proﬁle when used as an analgesic agent for
acute moderate to severe pain in children
presenting to the emergency department and
has been subsequently licensed in the UK for
acute severe pain in children.
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We report a large formal safety study of a diamorphine hydro-
chloride nasal spray.
METHODS
Design
The DIAmorphine SAFEty (DIASAFE) study was a multicentre,
open-label, single-dose, pharmacovigilance study in children in
the ED (recruiting April 2010–September 2011).
The study was approved by the regulatory authority and
appropriate research ethics committees. Eight EDs took part in
the safety study (see acknowledgements).
Population
Patients aged between 2 years and <16 years, weighing between
12 kg and 50 kg, with a suspected clinical fracture, or other
trauma requiring immediate pain relief with IND (in accordance
with usual practice).
Patients accompanied by a consenting parent or guardian
were eligible. Written informed consent was obtained from a
parent or guardian. Oral or written assent was also obtained
from the patient if the child was able (generally over 7 years).
An additional summary consent form was used to avoid delay in
provision of analgesia. Medical history, prior and current medi-
cations were recorded in each study.
Exclusion criteria included the presence of respiratory or
airways problems, history of epistaxis, head injury, opioid anal-
gesia or drugs known to interact with diamorphine in the pre-
ceding 7 days, or contraindications to the medication or
excipients.
Treatment
The product (Ayendi) comprises diamorphine hydrochloride BP
presented as a white freeze-dried powder in a vial (device
bottle), together with separate diluent for reconstitution (pre-
served 0.5% saline). The nasal spray is designed as a multiuse
product with replacement of the paediatric tip and priming
between patients. The diamorphine is delivered at a single dose
of 0.1 mg/kg±20%, using a total of 2–4 actuations of the
appropriate product strength directed into alternate nostrils,
according to weight. It is provided in two strengths: 144 mg
and 320 mg, providing 720 μg and 1600 μg diamorphine hydro-
chloride per actuation (50 μL), respectively, following reconstitu-
tion. The maximum volume administered per nostril is 100 μL;
the maximum total dose is 4.8 mg diamorphine hydrochloride
(three sprays of 1600 μg/actuation product). The small nasal
volume administered ensures that absorption of the whole dose
occurs transmucosally in the nares.
Each study site was provided with the two product strengths
in vials together with diluent. The diluent was added to the
bottle, the nasal spray pump (with paediatric nasal tip) attached,
and devices were prepared for initial use by priming the spray
eight times. Once reconstituted, sprays were stable at room tem-
perature and could remain in the controlled drug cabinet for up
to 14 days for multipatient use. A new paediatric tip was used
for each patient, with the spray being primed twice between
patients. Additional pain relief was allowed and was recorded.
Outcome measures
The primary outcome measures were observations related to the
safety of IND, with particular focus on nasal irritation, sedation,
central nervous system adverse events (AEs) and depression of
respiration.
Vital signs (oxygen saturation levels, RR, heart rate), pupil
dilation and Glasgow Coma Score (GCS) were recorded just
before treatment, and the nasal cavities were examined for signs
of abnormality. Vital signs (as above) and GCS were then mea-
sured immediately after diamorphine administration, at 15 min
intervals for the ﬁrst hour, and then every 30 min throughout
the study. The nasal cavities were assessed for signs of nasal irri-
tation every 30 min following diamorphine administration. All
treatment-emergent AEs (TEAEs) were recorded throughout the
child’s participation in the study, and for 7 days postdosing (if
reported to research staff spontaneously). All medication given
(including additional analgesia) was recorded throughout the
study duration.
Safety and quality assurance
An independent Data Safety Monitoring Committee reviewed
safety data after inclusion of 50 children and had oversight for
ongoing safety. The study was performed in compliance with
Good Clinical Practice Guidelines.
Statistical analysis
The data analysis and statistics reporting was conducted using
SAS V.9.2 (SAS Institute). All children who entered the study
and were treated were included in the safety analyses. Summary
statistics for quantitative data were produced, and for categorical
data, frequency tables were generated. Data were summarised
overall and by age group (2–11 years; 12–<16 years) as appro-
priate. Previous and concomitant medications were coded using
the World Health Organisation Drug Dictionary coding system.
AEs were coded using the MedDRA dictionary (V.13.0) and
relationship (causality), and severity of all events was evaluated
using WHO toxicity criteria. Serious AEs were classiﬁed accord-
ing to the Medicines and Healthcare Regulatory Agency’s deﬁn-
ition. Any events related to nasal irritation were speciﬁcally
grouped, reported separately and classiﬁed by type of irritation
(persistent and troublesome sneezing, redness, itching, local ten-
derness, swelling, nasal discharge or ‘other’) and severity.
In order to provide 95% conﬁdence of detecting reactions
occurring with >2% frequency, a minimum number of 150 chil-
dren was required.
RESULTS
Study population
Two hundred and twenty-six patients were recruited into
DIASAFE between April 2010 and September 2011, all of
whom received IND. One child was withdrawn from the study
due to rapid transfer to theatre for surgery, making further
observations impossible. Two hundred and twenty-ﬁve (191
aged 2–11 years, and 34 aged 12–<16 years) completed the
study. Table 1 shows the characteristics of children included. For
a number of children (56) study staff failed to follow study
protocol (the majority (36) of which were due to insufﬁcient
safety observations); this was anticipated in the emergency
setting and was reﬂected in the study sample size (226), with
over 150 children completed without major protocol deviation.
The majority of children attended with fractures (80%), most
of which were upper limb fractures. Burn injury was less fre-
quent (7%). Other presentations included amputation/partial
amputation, laceration and dislocation. A small number of chil-
dren had a history of previous medical problems, but none were
considered to be clinically relevant to the study.
Tables 2 and 3 show concomitant medication administered
before and during the DIASAFE study data collection period,
respectively.
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Safety
Adverse events
There were 87 TEAEs reported by 60 patients with 26.5%
(95% CI 20.9% to 32.8%) of patients reporting one or more
events, 25.1% of the younger children (2–11 years), and 34.3%
of the older children (12–<16) (table 4). No events were severe
or serious. Most AEs were mild (93%) except ﬁve moderate AEs
in three patients (all resolved by discharge) and one event not
given a severity rating (resolved by discharge).
The most common events involved the respiratory system (53
events in 45 children) including nasal discomfort (24 children)
and sneezing (22 children). Nervous system disorders were
Table 2 Children given medicines before receiving IND in the
DIASAFE STUDY
Medications
No. of
patients
Percentage of total
patients* (%)
Patients given medication prior to IND 136 60.2
Painkillers
Paracetamol 117 51.8
Ibuprofen 92 40.7
Entonox 36 15.9
Oramorph 5 2.2
*To 1 decimal place.
IND, intranasal diamorphine.
Table 1 Characteristics of the children in the DIASAFE study
Statistics
Age group
2–11 years
(N=191)
Age group
12–<16 years
(N=35)
Overall
(N=226)
Age (years)
Mean 6.6 12.9 7.6
SD 2.91 0.89 3.54
Minimum 1 12 1
Median 6.0 13.0 7.0
Maximum 11 15 15
Gender n (%)
Male 110 (57.6) 27 (77.1) 137 (60.6)
Female 81 (42.4) 8 (22.9) 89 (39.4)
Race n (%)
White 169 (88.5) 31 (88.6) 200 (88.5)
Black 5 (2.6) 2 (5.7) 7 (3.1)
Asian 6 (3.1) 2 (5.7) 8 (3.5)
Other 7 (3.7) 0 7 (3.1)
Unknown 4 (2.1) 0 4 (1.8)
Weight (kg)
Mean 26.46 43.01 29.03
SD 9.64 5.58 10.92
Minimum 12.0 30.6 12.0
Median 24.00 43.30 26.60
Maximum 50.0 50.5 50.5
Nasal application site n (%)
Normal 189 (99.0)* 35 (100.0) 224 (99.1)*
Abnormal 0 0 0
(%)=n/N×100 for categorical variables.
*In two children, there was no recording of nasal application site (no adverse events
related to nasal irritation in these children).
N, the number of patients in the population.
n, the number of patients meeting the criterion.
Table 3 Children given concomitant medicines in the DIASAFE
study
Concomitant Medications
No. of
patients
Percentage of total
patients*
Patients given medication post-IND 100 44.4
Painkillers
Paracetamol 47 20.8
Ibuprofen 44 19.5
Entonox 20 8.8
Diclofenac 1 0.4
Opiate (non-IMP) 10 4.4
Asthma treatment
Salbutamol 6 2.7
Beclometasone 4 1.8
Fluticasone 1 0.4
Antihistamine (chlorpheniramine) 2 0.9
Other
Topical/local anaesthetic 7 3.1
Antibiotic 6 2.7
Midazolam 1 0.4
Ketamine 3 1.3
*To 1 decimal place.
IMP, investigational medicinal product; IND, intranasal diamorphine.
Table 4 DIASAFE adverse event overview
Body system
N=226
Total number of events (number
of patients)
Respiratory, thoracic and mediastinal
disorders
53 (45)
Nervous system disorders 15 (11)
Dysgeusia 5
Dizziness 4
Somnolence 3
Paraesthesia mucosal 2
Depressed level of consciousness 1
Gastrointestinal disorders 11 (9)
General disorders and administration site
conditions
3 (3)
Skin and subcutaneous tissue disorders 2 (2)
Psychiatric disorders 1 (1)
Anxiety 1
Eye disorders 1 (1)
Vascular disorders 1 (1)
Injury, poisoning and procedural
complications
Total number of events (number of
patients)
87 Total
10 Non-related*
77 Related†
81 Mild
5 Moderate
0 Severe
1 Unknown severity
*Non-related events are defined as Unlikely or Unrelated to study medication.
†Related events are defined as Definite, Probably or Possibly related to study
medication.
N, the number of patients in the population.
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reported by 11 children, the most common being an unpleasant
taste (ﬁve children). Nine children reported gastrointestinal-
related events (11 events, including vomiting in seven children).
The majority (88.5%) of AEs (77 events in 54 children) were
considered to be causally related to treatment, and were antici-
pated due to the drug itself or route of administration, with the
exception of three events in two children: moderate itchy eyes
in one child and mild pallor and ‘feeling hot’ in another.
The percentage of patients experiencing an AE was higher in
the older age group than in the younger (34.3% vs 25.1%).
Ten children experienced an AE after discharge from the ED,
reporting 13 AEs, most of which (12) were mild. One child
experienced moderate vomiting.
Any vital signs measure or reduction in GCS score that the
investigator considered clinically relevant for the study was to
be reported as an AE. No vital sign measures were reported as
AEs.
Three children had AEs recorded that were associated with a
decrease in GCS, all mild, and considered to be causally related
to IND. All but one resolved within the study period, in this
case the GCS value returned to normal at 50 min after dosing.
Nasal tolerability
There were 20.4% (95% CI 15.3% to 26.2%) of patients who
reported at least one nasal AE, 19.9% of the younger children
(2–11 years), and 22.9% of the older children (12–<16 years)
(table 5). There were 52 mild, one moderate and one unclassi-
ﬁed AEs related to nasal irritation reported by 46 children. The
most common was itching reported by 22 patients, all consid-
ered to be mild except one (moderate). Persistent and trouble-
some sneezing (mild) was reported by nine patients. There were
single reports of mild redness, and mild nasal discharge. The
remainder of the events were classiﬁed as ‘Other’ (19 patients)
which included instances of a single sneeze following adminis-
tration. No patient reported local tenderness or swelling. No
further nasal AEs were seen after discharge.
Most (45 out of 54 (83.3%)) nasal AEs occurred within
30 min of dosing, seven between 30 min and 1 h, and two
started beyond 1 h of dosing. Most events (76%) resolved
within 1 h (37% within 5 min), with 11% resolving later than
1 h. The remaining 13% had an unknown resolution time. The
onset and resolution of AEs is consistent with the short half-life
of diamorphine and its active metabolites.
The majority of patients reporting nasal events were treated
with higher strength (1600 μg/actuation) spray (32 (70%)).
However, there was not an increased reporting rate in patients
administered two sprays per nostril versus one spray per nostril.
DISCUSSION
The DIASAFE study was designed with sufﬁcient sample size to
ensure (with 95% probability) that at least one child would
experience any particular AE, if the underlying event rate was at
least 2%. As with other opiates, the main adverse effects of dia-
morphine include respiratory depression, sedation, nausea and
vomiting, constipation and sweating. In this study, there was no
evidence of clinically signiﬁcant respiratory depression, and only
minor reductions in the level of consciousness in children. The
incidence of vomiting was as expected and considered to be
acceptable.
A potential concern of IND is local (nasal) tolerability. No
incidence of swelling or tenderness was seen, although a small
number of children reported mild itching (with one moderate
itching) or mild sneezing. Nasal irritation does not appear to be
directly related to the volume administered per se, but just due
Table 5 DIASAFE adverse events relating to nasal irritation
Classification type Severity*
Age group 2–11 years (N=191)
Patients (%)
Age group 12-<16 years (N=35)
Patients (%)
Overall (N=226)
Patients (%)
Patients with any nasal irritation TEAE Overall 38 (19.9) 8 (22.9) 46 (20.4)
Mild 36 (18.8) 8 (22.9) 44 (19.5)
Moderate 1 (0.5) 0 1 (0.4)
Severe 0 0 0
Unknown 1 (0.5) 0 1 (0.4)
Persistent and troublesome Sneezing Overall 5 (2.6) 4 (11.4) 9 (4.0)
Mild 5 (2.6) 4 (11.4) 9 (4.0)
Redness Overall 1 (0.5) 0 1 (0.4)
Mild 1 (0.5) 0 1 (0.4)
Itching Overall 20 (10.5) 2 (5.7) 22 (9.7)
Mild 19 (9.9) 2 (5.7) 21 (9.3)
Moderate 1 (0.5) 0 1 (0.4)
Nasal discharge Overall 0 1 (2.9) 1 (0.4)
Mild 0 1 (2.9) 1 (0.4)
Other—nasal discomfort Overall 4 (2.1) 1 (2.9) 5 (2.2)
Mild 3 (1.6) 1 (2.9) 4 (1.8)
Unknown 1 (0.5) 0 1 (0.4)†
Other—sneezing Overall 11 (5.8) 3 (8.6) 14 (6.2)
Mild 11 (5.8) 3 (8.6) 14 (6.2)
Local tenderness Overall 0 0 0
Swelling Overall 0 0 0
Treatment emergent adverse events (TEAEs) are defined as adverse events that started or worsened after first administration of the investigational medicinal product.
TEAEs relating to nasal irritation were identified and classification type assigned to each event prior to database lock.
If a patient experienced more than one TEAE relating to nasal irritation, the patient is counted once for each classification type, at the highest severity. MedDRA dictionary V.13.0 was
used for coding adverse events. N=the number of patients in the population.
(%)=patients/N×100.
*Severity only displayed when an event was seen at that severity.
†Patient reported ‘nasal irritation’ with no classification or severity noted.
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to exposure to the product in those sensitive to the drug, excipi-
ents or nasal administration in general. The severity of irritation
has been mild only, except for one moderately severe report,
and one report which was not graded, but no sequelae were
reported.
The incidence of AEs in the DIASAFE study (26.5%) is similar
to the Kendall study (24.5%)11 which compared safety and efﬁ-
cacy of IND with intramuscular morphine sulfate; speciﬁc attri-
bution of events was not recorded in this earlier study. The
incidence of AEs related to nasal irritation, however, was higher
in the DIASAFE study compared to the Kendall study11 (20.4%
patients vs 13.2%). This was expected, because nasal irritation
was systematically evaluated in the DIASAFE study in line with
study objectives. In the Kendall study, nasal irritation was assessed
by staff at the time of treatment administration, and thereafter
evaluated ad hoc by asking patients if they had irritation rather
than speciﬁcally assessing the site of administration.
The DIASAFE study was carried out in Teaching and District
General Hospital EDs, some of which had dedicated paediatric
EDs, with varying local population catchment areas and charac-
teristics. Thus, children in this trial are representative of those
presenting to EDs throughout the UK. Our studies were unable
to evaluate rare AEs due to the limited sample size.
OVERALL CONCLUSION
There were no safety concerns raised during the conduct of the
study. In addition to the expected side effects of dose-related
opioid sedation and gastrointestinal effects, IND can cause mild
nasal irritation in a proportion of patients. A dose of 0.1 mg/kg
appears appropriate in the ED setting. Overall diamorphine
nasal spray shows a good safety proﬁle.
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